- Associated Press - Thursday, April 27, 2017

GENEVA (AP) - Swiss pharmaceuticals company Roche says revenues rose 4 percent in the first quarter, powered partly by improved U.S. sales of two recently launched cancer medicines.

The Basel-based company, a leading cancer-drug specialist, reported sales of 12.9 billion Swiss francs ($13 billion dollars).

U.S. sales climbed 6 percent thanks to recent release of Tecentriq, for some types of bladder and lung cancer, and Alcensa for lung cancer.

Sales of Roche’s top seller MabThera/Rituxan, for some types of blood cancer, rheumatoid arthritis and vasculitis, rose 4 percent to 1.9 billion francs. Generic competition dented sales of flu treatment Tamiflu.

CEO Severin Schwan hailed U.S. approval for multiple sclerosis treatment Ocrevus, and said Roche was on track to meet its 2017 targets: Sales are expected to grow in low- to mid-single-digit percentage points.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide